肿瘤细胞治疗研究
英文原题：Therapeutic targeting of the protein tyrosine kinase-7 in cancer: an overview.
Therapeutic targeting of the protein tyrosine kinase-7 in cancer: an overview.
蛋白酪氨酸激酶-7（PTK7）是一种进化上保守的跨膜受体，已成为人类肿瘤的潜在治疗靶点。
蛋白酪氨酸激酶7（PTK7）是一种进化上保守的跨膜受体，已成为人类肿瘤潜在的治疗靶点。PTK7是一种假激酶，可通过与其他受体相互作用调节Wnt信号通路。这些相互作用会导致靶基因活化，在胚胎发育过程中调控细胞极性、迁移和增殖。除发育过程中的作用外，研究还发现PTK7在多种癌症中过表达，包括结肠癌、白血病、神经母细胞瘤、肝癌和卵巢癌。PTK7的活性及其与不良预后的直接相关性，推动了抑制PTK7并诱导抗肿瘤效应的临床前研究和I期临床试验。本综述全面概述了将PTK7作为新型分子靶点、用于不同肿瘤类型癌症治疗的多种方法。基于最新文献和持续推进的研究，我们讨论当前疗法及未来策略，包括CAR-T 细胞、抗体药物偶联物和适配体。
The protein tyrosine kinase-7 (PTK7) is an evolutionarily conserved transmembrane receptor that has emerged as a potential therapeutic target for human tumors. PTK7 is a pseudokinase that is involved in the modulation of the Wnt signaling pathway through interactions with other receptors. These interactions result in targeted gene activation that regulates cell polarity, migration, and proliferation during embryogenesis. Aside of this role during development, PTK7 has been shown as overexpressed in numerous cancers including colon carcinoma, leukemia, neuroblastoma, hepatoma, and ovarian cancer. The activity of PTK7 and the direct correlation with poor prognosis have fostered preclinical investigations and phase I clinical trials, aiming at inhibiting PTK7 and inducing antitumoral effects. In this review, we provide an exhaustive overview of the diverse approaches that use PTK7 as a new molecular target for cancer therapy in different tumor types. We discuss current therapies and future strategies including chimeric antigen receptor-T cells, antibody-drug conjugates, aptamers, based on up-to-date literature and ongoing research progress.
MEMBER ACCOUNT
登录成功会直接打开下一页。
